EA201890113A1 - Композиции и способы ингибирования активности аргиназы - Google Patents
Композиции и способы ингибирования активности аргиназыInfo
- Publication number
- EA201890113A1 EA201890113A1 EA201890113A EA201890113A EA201890113A1 EA 201890113 A1 EA201890113 A1 EA 201890113A1 EA 201890113 A EA201890113 A EA 201890113A EA 201890113 A EA201890113 A EA 201890113A EA 201890113 A1 EA201890113 A1 EA 201890113A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- compositions
- arginase activity
- inhibiting arginase
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183524P | 2015-06-23 | 2015-06-23 | |
| PCT/US2016/038983 WO2016210106A1 (en) | 2015-06-23 | 2016-06-23 | Compositions and methods for inhibiting arginase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890113A1 true EA201890113A1 (ru) | 2018-07-31 |
Family
ID=57585664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890113A EA201890113A1 (ru) | 2015-06-23 | 2016-06-23 | Композиции и способы ингибирования активности аргиназы |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10143699B2 (enExample) |
| EP (1) | EP3313410A4 (enExample) |
| JP (2) | JP2018520352A (enExample) |
| KR (1) | KR20180021117A (enExample) |
| CN (1) | CN107921051A (enExample) |
| AU (1) | AU2016281620B2 (enExample) |
| CA (1) | CA2990192A1 (enExample) |
| EA (1) | EA201890113A1 (enExample) |
| IL (1) | IL256352A (enExample) |
| MA (1) | MA42269A (enExample) |
| MX (1) | MX385315B (enExample) |
| MY (1) | MY192605A (enExample) |
| PH (1) | PH12017502391A1 (enExample) |
| SG (1) | SG10202110144TA (enExample) |
| UA (1) | UA123700C2 (enExample) |
| WO (1) | WO2016210106A1 (enExample) |
| ZA (1) | ZA201800328B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201503168VA (en) | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| HUE027317T2 (en) | 2010-10-26 | 2016-10-28 | Mars Inc | Boronates as arginase inhibitors |
| UA123700C2 (uk) | 2015-06-23 | 2021-05-19 | Калітера Байосайєнсиз, Інк. | Композиції і способи інгібування активності аргінази |
| HRP20201046T1 (hr) * | 2015-10-30 | 2020-10-16 | Calithera Biosciences, Inc. | Sastavi i metode za inhibitivnu aktivnost arginase |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| KR20190104521A (ko) | 2016-11-08 | 2019-09-10 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 억제제 병용 요법들 |
| PE20191541A1 (es) | 2016-12-22 | 2019-10-23 | Calithera Biosciences Inc | Composiciones y metodos para inhibir la accion de la arginasa |
| CN108794517B (zh) * | 2017-04-27 | 2021-03-30 | 南京谷睿生物科技有限公司 | 一种精氨酸酶抑制剂及其制备方法与用途 |
| BR112019023582A2 (pt) | 2017-05-12 | 2020-06-02 | Calithera Biosciences Inc. | Método de preparar (3r,4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida |
| WO2019000163A1 (zh) * | 2017-06-26 | 2019-01-03 | 余祖江 | 精氨酸在制备抗肿瘤药物中的用途 |
| CN111491937A (zh) * | 2017-12-22 | 2020-08-04 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的杂环化合物 |
| MA51837A (fr) * | 2018-02-17 | 2021-06-16 | Astrazeneca Ab | Inhibiteurs de l'arginase et leurs procédés d'utilisation |
| UA127897C2 (uk) * | 2018-03-05 | 2024-02-07 | Аркус Байосайєнсіз, Інк. | Інгібітори аргінази |
| TWI723366B (zh) | 2018-03-29 | 2021-04-01 | 波蘭商昂科艾倫迪治療法股份公司 | 二肽哌啶衍生物 |
| WO2019205979A1 (zh) * | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
| JP7441210B2 (ja) * | 2018-08-22 | 2024-02-29 | アストラゼネカ・アクチエボラーグ | アルギナーゼインヒビタ及びその使用方法 |
| CA3120196A1 (en) * | 2018-11-16 | 2020-05-22 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| WO2020104626A1 (en) * | 2018-11-21 | 2020-05-28 | Black Belt Tx Ltd | Inhibitors of arginase |
| EP3917936A4 (en) * | 2019-02-06 | 2022-12-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | ALKYBORONIC ACIDS AS ARGINASE INHIBITORS |
| BR112021015581A2 (pt) * | 2019-02-08 | 2021-10-05 | Astrazeneca Ab | Inibidores de arginase e seus métodos de uso |
| US10967020B2 (en) * | 2019-04-05 | 2021-04-06 | King Saud University | Method of synthesizing custard apple peel nanoparticles |
| CN112110944B (zh) * | 2019-06-21 | 2022-02-11 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和应用 |
| EP4004004A1 (en) * | 2019-07-23 | 2022-06-01 | AstraZeneca AB | Arginase inhibitors and methods of use thereof |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| US20250099408A1 (en) | 2022-01-21 | 2025-03-27 | Sammy Oyoo OPIYO | Improved suramin methods and compositions |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| DE69818675T2 (de) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| WO1999019295A1 (en) | 1997-10-10 | 1999-04-22 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（−）−ビュープロピオンの薬学的使用 |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| CA2415174A1 (en) * | 2000-07-06 | 2002-01-17 | Thomas W. Bell | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| ES2332049T5 (es) | 2003-08-07 | 2014-03-27 | Allergan, Inc. | Composiciones de administración de sustancias terapéuticas en los ojos |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US20090298912A1 (en) | 2005-07-01 | 2009-12-03 | The Johns Hopkins University | Arginase II: A Target treatment of aging heart and heart failure |
| CN101755130B (zh) | 2007-07-12 | 2012-10-17 | 山洋电气株式会社 | 双重反转式轴流鼓风机 |
| SMT201900320T1 (it) | 2009-01-26 | 2019-07-11 | Astrazeneca Uk Ltd | Inibitori dell'arginasi e metodi di utilizzo |
| SG10201503168VA (en) | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| HUE027317T2 (en) * | 2010-10-26 | 2016-10-28 | Mars Inc | Boronates as arginase inhibitors |
| WO2012091757A1 (en) | 2010-12-31 | 2012-07-05 | Corridor Pharmaceuticals, Inc. | Arginase inhibitors and methods of use thereof |
| JP5993459B2 (ja) | 2011-10-19 | 2016-09-14 | マーズ インコーポレイテッド | アルギナーゼ阻害剤およびそれらの治療用途 |
| KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| JP6152167B2 (ja) * | 2012-04-18 | 2017-06-21 | マーズ インコーポレイテッド | アルギナーゼ阻害剤としての環拘束性類似体 |
| CN105848680A (zh) | 2013-10-25 | 2016-08-10 | 药品循环有限责任公司 | 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗 |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| CN107405404A (zh) | 2015-03-20 | 2017-11-28 | 塞米·欧尤·奥皮约 | 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途 |
| UA123700C2 (uk) | 2015-06-23 | 2021-05-19 | Калітера Байосайєнсиз, Інк. | Композиції і способи інгібування активності аргінази |
-
2016
- 2016-06-23 UA UAA201800583A patent/UA123700C2/uk unknown
- 2016-06-23 EA EA201890113A patent/EA201890113A1/ru unknown
- 2016-06-23 MY MYPI2017704875A patent/MY192605A/en unknown
- 2016-06-23 MA MA042269A patent/MA42269A/fr unknown
- 2016-06-23 EP EP16815284.1A patent/EP3313410A4/en not_active Withdrawn
- 2016-06-23 WO PCT/US2016/038983 patent/WO2016210106A1/en not_active Ceased
- 2016-06-23 JP JP2017567207A patent/JP2018520352A/ja not_active Ceased
- 2016-06-23 US US15/190,653 patent/US10143699B2/en active Active
- 2016-06-23 AU AU2016281620A patent/AU2016281620B2/en not_active Ceased
- 2016-06-23 MX MX2017016868A patent/MX385315B/es unknown
- 2016-06-23 SG SG10202110144T patent/SG10202110144TA/en unknown
- 2016-06-23 KR KR1020187002201A patent/KR20180021117A/ko not_active Ceased
- 2016-06-23 CA CA2990192A patent/CA2990192A1/en not_active Abandoned
- 2016-06-23 CN CN201680048714.7A patent/CN107921051A/zh active Pending
-
2017
- 2017-12-17 IL IL256352A patent/IL256352A/en unknown
- 2017-12-21 PH PH12017502391A patent/PH12017502391A1/en unknown
-
2018
- 2018-01-17 ZA ZA2018/00328A patent/ZA201800328B/en unknown
- 2018-08-27 US US16/113,816 patent/US10398714B2/en not_active Expired - Fee Related
-
2019
- 2019-07-29 US US16/525,403 patent/US10905701B2/en not_active Expired - Fee Related
-
2020
- 2020-11-19 US US16/953,125 patent/US20210077510A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021128745A patent/JP2021185146A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017016868A (es) | 2018-09-06 |
| JP2021185146A (ja) | 2021-12-09 |
| ZA201800328B (en) | 2018-12-19 |
| MX385315B (es) | 2025-03-14 |
| WO2016210106A1 (en) | 2016-12-29 |
| UA123700C2 (uk) | 2021-05-19 |
| US20160375044A1 (en) | 2016-12-29 |
| JP2018520352A (ja) | 2018-07-26 |
| US10398714B2 (en) | 2019-09-03 |
| PH12017502391A1 (en) | 2018-06-25 |
| SG10202110144TA (en) | 2021-10-28 |
| US20190343852A1 (en) | 2019-11-14 |
| MY192605A (en) | 2022-08-29 |
| MA42269A (fr) | 2018-05-02 |
| AU2016281620B2 (en) | 2021-07-22 |
| US20210077510A1 (en) | 2021-03-18 |
| IL256352A (en) | 2018-02-28 |
| EP3313410A4 (en) | 2019-01-02 |
| US10905701B2 (en) | 2021-02-02 |
| EP3313410A1 (en) | 2018-05-02 |
| KR20180021117A (ko) | 2018-02-28 |
| AU2016281620A1 (en) | 2018-02-15 |
| US10143699B2 (en) | 2018-12-04 |
| CN107921051A (zh) | 2018-04-17 |
| CA2990192A1 (en) | 2016-12-29 |
| US20180360860A1 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890113A1 (ru) | Композиции и способы ингибирования активности аргиназы | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| EA201591069A1 (ru) | Лечение злокачественной опухоли гетероциклическими ингибиторами глутаминазы | |
| EA201891057A1 (ru) | Композиции и способы для ингибирования активности аргиназы | |
| MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
| MX384792B (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX382339B (es) | Inhibidores g12c de kras. | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| EA201792186A1 (ru) | Ингибиторы индоламин-2,3-диоксигеназы и способы их применения | |
| EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
| EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
| EA201591705A1 (ru) | Композиции и способы для диагностики и лечения рака печени | |
| MX386565B (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. | |
| MX369609B (es) | Una composición para usarse en el tratamiento de cáncer deficiente en nmt2. | |
| EA201792580A1 (ru) | Ингибиторы ido | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
| EA201790484A1 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
| MX388409B (es) | Composiciones y metodos para tratar canceres. | |
| MX394015B (es) | Inhibición de la actividad de la olig2. | |
| EA201591304A1 (ru) | Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке | |
| EA201992200A1 (ru) | Микроинкапсулированные композиции ингибиторов нитрификации |